An observational study in Sudden Cardiac Death, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Open to participants aged 16 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-05.
Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Death, Sudden, Cardiac with a site in China — 9 open to participants now, 10 under way, none of them phase 3. Death, Sudden, Cardiac · China.
Among the 19 studies in Death, Sudden, Cardiac with a site in China, this one has the largest planned enrollment of the 15 observational ones that give a count, is one of 2 that started in 2023, is one of 15 observational ones, and was the 10th registered.
364 studies on the registry are indexed under Death, Sudden, Cardiac; 84 are open to participants now.
Browse Death, Sudden, Cardiac studies →9 of the 19 studies in Death, Sudden, Cardiac with a site in China are open now. Recruiting first, the newest first:
Beijing Anzhen Hospital · Sites in China
Ages 18–80
Chensheng Pan · Sites in China
Ages 18+
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 18+
Shandong Provincial Hospital · Sites in China
Ages 18+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 63 Death, Sudden, Cardiac studies recruiting now, 42 (67%) set no upper age limit and 11 (17%) stop at 75 or younger; 22 take children under 18; 7 take healthy volunteers.
This study: 16 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 100,000 is above the median of 450 across 203 observational studies indexed under Death, Sudden, Cardiac.
Median enrollment 342 across the 4 interventional studies, 1,491 across the 15 observational. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 19 have an industry lead sponsor. The 10 most frequent:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the lead sponsor of 485 studies on the registry; 279 are open to participants now.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University has 2 studies filed under Death, Sudden, Cardiac — fewer than ten, so there is no comparison to draw.
2 of the studies in Death, Sudden, Cardiac with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06856993The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolEarly Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death | 2026-12-31 |
| NCT07476456China National Center for Cardiovascular DiseasesSkeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Death, Sudden, Cardiac with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to identify potential indicators for pre-warning of sudden cardiac death (SCD), including clinical biochemistry markers, electrocardiogram, echocardiography, MRI and CT imaging values, genetic markers and so on, and further construct a series of multi-parameter assessments of SCD early screening.
In the past few decades, evidence-based drug and surgical treatment strategies have significantly improved the prevention of sudden cardiac death (SCD), however, a large number of patients with cardiovascular disease still face high risk of SCD, the prognosis of these high-risk SCD patients are still uncertain. Therefore, clinical physicians might need to move towards a multi-parameter assessment of SCD risk pre-warning. Several parameters for risk stratification of arrhythmia, including clinical biochemistry markers, electrocardiogram, echocardiography, imaging, and genetic markers, are crucial for accurate assessment of SCD risk stratification. In addition, the integration of cardiac magnetic resonance parameters and specific CT and ECG information is a future research trend for implementing risk stratification of malignant arrhythmias. In order to further explore the possibility of early warning of SCD, this study aims to include subjects with potential SCD risks, collect relevant potential SCD warning indicators, and then construct an SCD prewarning score system. Afterwards, the investigators will continuously improve the SCD warning score system based on follow-up information, and ultimately summarize an effective set of SCD warning scores and apply them to clinical practice, striving to achieve early warning of SCD and benefiting more people at risk of SCD.
Participants with potential high-risk of sudden cardiac death.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The subjects with the following diagnosis of one or more cardiovascular diseases:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sudden cardiac death
Identify participants who die by cardiovascular diseases during follow-up period
Time frame: Baseline and to the 1-year, 2-year, 5-year follow-up
All-causes death
Identify participants who die during follow-up period
Time frame: Baseline and to the 1-year, 2-year, 5-year follow-up
Recurrence of cardiovascular disease
Identify participants who with recurrence of cardiovascular disease during follow-up period
Time frame: Baseline and to the 1-year, 2-year, 5-year follow-up
Cardiac arrest
Identify participants who suffer sudden cardiac arrest during follow-up period
Time frame: Baseline and to the 1-year, 2-year, 5-year follow-up
Major cardiovascular events
Identify participants who suffer incident major cardiovascular events during follow-up period
Time frame: Baseline and to the 1-year, 2-year, 5-year follow-up
Started Mar 2023 (actual). Primary completion is estimated for Dec 2027, 57 months after the start.
Of 70 non-industry observational studies under Death, Sudden, Cardiac, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 42. This study's planned 57 months is below that.
Counting every sponsor, half of 86 studies reached it within 63 months; a quarter within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University →